CE Celanese Corporation

Celanese Appoints Peter Edwards as General Counsel

Celanese Corporation (NYSE: CE), a global technology and specialty materials company, today announces the appointment of Peter Edwards as the company’s General Counsel effective end of January 2017.

Edwards is a seasoned public company General Counsel with extensive experience working in highly regulated, global organizations. He most recently served as Executive Vice President and General Counsel of Baxalta Inc., a biopharmaceutical spin-off of Baxter International.

Edwards has worked for the multinational pharmaceutical company Eli Lilly and Company, as well as for mid-sized companies such as Solvay Pharmaceuticals and Mallinckrodt (formerly Covidien Pharmaceuticals). Additionally, Edwards has substantial international experience including his role as Executive Vice President and General Counsel for Solvay Pharmaceuticals, when he was based in Brussels, Belgium. During his various roles, Edwards has also acquired significant legal and business expertise in the area of merger and acquisition (M&A) law.

“Peter’s breadth of technical legal skills, high business acumen and international experience will be a most valuable addition to Celanese,” said Mark Rohr, Celanese Chairman and Chief Executive Officer. “We welcome Peter to his new General Counsel role leading the company’s Law Department and I am confident his experience will be instrumental to Celanese as we continue seek opportunities to expand our M&A pipeline, market access and product portfolio.”

About Celanese

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our two complementary business cores, Acetyl Chain and Materials Solutions, use the full breadth of Celanese’s global chemistry, technology and business expertise to create value for our customers and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,000 employees worldwide and had 2015 net sales of $5.7 billion. For more information about Celanese and our product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

All registered trademarks are owned by Celanese International Corporation or its affiliates.

EN
26/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celanese Corporation

 PRESS RELEASE

Celanese Announces Early Results and Upsize of Tender Offers for 6.665...

Celanese Announces Early Results and Upsize of Tender Offers for 6.665% Senior Notes due 2027 and 6.850% Senior Notes due 2028 DALLAS, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Celanese Corporation (NYSE: CE) (“Celanese”), a global chemical and specialty materials company, today announced the early results of offers by its direct wholly-owned subsidiary Celanese US Holdings LLC (the “Company”) to purchase for cash validly tendered (and not validly withdrawn) and accepted notes in an aggregate principal amount equal to (i) $946,106,000 of 6.665% Senior Notes due 2027 (the “2027 Notes”) and (ii) $2...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Celanese Corp: 1 director

A director at Celanese Corp bought 5,000 shares at 41.030USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch